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In animal models, inflammatory processes have been shown
to have an important role in the development of kidney
disease. In humans, however, the independent relation
between markers of inflammation and the risk of chronic
kidney disease (CKD) is not known. To clarify this, we
examined the relationship of several inflammatory biomarker
levels (high-sensitivity C-reactive protein, tumor necrosis
factor-a receptor 2, white blood cell count, and interleukin-6)
with the risk of developing CKD in a population-based
cohort of up to 4926 patients with 15 years of follow-up.
In cross-sectional analyses, we found that all these
inflammation markers were positively associated with the
outcome of interest, prevalent CKD. However, in longitudinal
analyses examining the risk of developing incident CKD
among those who were CKD-free at baseline, only tumor
necrosis factor-a receptor 2, white blood cell count, and
interleukin-6 levels (hazard ratios comparing highest with the
lowest tertile of 2.10, 1.90, and 1.45, respectively), and not C-
reactive protein (hazard ratio 1.09), were positively
associated with incident CKD. Thus, elevations of most
markers of inflammation predict the risk of developing CKD.
Each marker should be independently verified.
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Chronic kidney disease (CKD) involves several pathophysio-
logical mechanisms that are analogous to atherosclerosis.1
Inflammatory processes are considered to have a key role in
atherosclerosis development.2 Markers of inflammation are
implicated in the development of diabetes mellitus3,4 and
hypertension,5 which are strong risk factors for CKD.6 In
animal models, inflammatory processes have been shown to
have an important role in kidney disease development.7–11
However, in humans, the independent relationship between
markers of inflammation and the risk of developing CKD is
not clear. In this context, we examined the independent
relationship between markers of inflammation and the risk of
developing CKD over a period of 15 years in a population-
based cohort study of predominantly White subjects from
Wisconsin who were free of CKD at baseline.
RESULTS
For the cross-sectional analysis, after exclusions (Figure 1),
4124 subjects with complete covariate data were available for
the white blood cell (WBC) count and C-reactive protein
(CRP) analyses, and 1503 subjects for the tumor necrosis
factor-alpha receptor 2 level (TNF-aR2) and interleukin (IL)-
6 analyses. Similarly, for the longitudinal analysis (Figure 2),
2877 subjects were available for the WBC count and CRP
analyses, and 1508 subjects for the TNF-aR2 and IL-6
analyses.
Table 1 presents the baseline characteristics of the cohort
for the serum TNF-aR2-incident CKD analysis. Subjects with
higher TNF-aR2 levels were more likely to be older, a current
smoker, a never or former drinker, more likely to haveohigh
school education, a higher body mass index, diabetes
mellitus, hypertension, higher systolic blood pressure, less
likely to be a former smoker, and less likely to have 4high
school education.
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Similar to Table 1, we examined the baseline character-
istics of the cohort by increasing tertiles of other markers of
inflammation, including serum CRP, IL-6, and WBC count
(data not presented). We found that the findings were
essentially similar to the results for TNF-a receptor 2 analysis
in Table 1, except that the inverse association with former
smoking was not statistically significant for IL-6 (P¼ 0.071).
Table 2 presents the distribution of estimated glomerular
filtration rate (eGFR) categories in the baseline cohort and
how the mean level of each marker of inflammation varied
with increasing severity of kidney function. Approximately
85% of the study subjects had an eGFRX60ml/min per
1.73m2, whereas 0.5% had an eGFRo30ml/min per 1.73m2.
We found that the mean level of each marker of inflamma-
tion increased with worsening kidney function.
Table 3 presents the cross-sectional association between
increasing categories of serum CRP, TNF-aR2, IL-6, WBC
count, and prevalent CKD. Overall, all the markers of
inflammation were found to be positively associated with
prevalent CKD in both the age- and sex-adjusted model and
the multivariable-adjusted model. Corresponding models of
trend were also statistically significant.
Table 4 presents the longitudinal associations between
increasing categories of serum CRP, TNF-aR2, IL-6, WBC
count, and 15-year incident CKD. We ran multivariable
models initially without (multivariable-adjusted hazard ratio
1) and subsequently with adjustment for diabetes and
hypertension (multivariable-adjusted hazard ratio 2) to study
the effect of statistical adjustment for these variables, which
are potential mediators. We found that there was no
appreciable attenuation of the association between these
markers of inflammation and 15-year incident CKD with
additional adjustment for diabetes and hypertension.
In Table 4, for the CRP analysis, there was no associa-
tion between increasing CRP levels and incident CKD
(P-trend¼ 0.42 in the multivariable model 2). In contrast,
for the TNF-aR2 analysis, a positive association between
increasing TNF-aR2 levels and incident CKD (P-trend
o0.0001 in the multivariable mode 2) was present. Similar
positive associations, although of lesser magnitude, were
observed for WBC count and IL-6.
We also performed several supplementary analyses.
First, to examine whether the positive association observed
between increasing TNF-aR2 levels and 15-year incident
CKD in the longitudinal analysis was independent of other
inflammatory markers (CRP, WBC count, and IL-6 levels),
we additionally adjusted for levels of these markers as a
continuous variable in the multivariable model. The results
were attenuated, but a positive association persisted for
TNF-aR2. Compared with the lowest tertile of TNF-aR2
(referent), the HR (95% confidence interval (CI)) of CKD
was 1.24 (0.90, 1.71) in the second tertile and 1.68 (1.29,
2.19) in the highest tertile; P-trend¼ 0.002. Second, to avoid
the possibility of reverse causality, we repeated the
main analysis after excluding the CKD cases occurring
during the initial 5 years of follow-up. The overall results
were similar; however, the magnitude of association was
slightly attenuated for TNF-aR2 results. For the CRP analysis,
compared with the lowest tertile (referent), the HR (95% CI)
of CKD was 1.06 (0.81, 1.39) in the second tertile and 1.09
(0.86, 1.38) in the highest tertile; P-trend¼ 0.42. For
TNF-aR2 analysis, compared with the lowest tertile (refer-
ent), the HR (95% CI) of CKD was 1.47 (0.89, 2.43) in the
second tertile and 1.90 (1.11, 3.25) in the highest tertile;
P-trendo0.0001.
Finally, defining CKD as both an eGFR falling below
60ml/min per 1.73m2 and a decrease in eGFR of at least 25%
over the follow-up period as suggested by Bash et al.,12 there
were 350 incident cases of CKD for the CRP analysis and
143 incident CKD cases for the TNF-aR2 analysis over the
15-year follow-up period. For the CRP analysis, compared
with the lowest tertile (referent), the HR (95% CI) of CKD
was 1.12 (0.84, 1.49) in the second tertile and 1.08
(0.88, 1.33) in the highest tertile; P-trend¼ 0.51. For TNF-
aR2 analysis, compared with the lowest tertile (referent),
the HR (95% CI) of CKD was 1.54 (0.88, 2.70) in the
second tertile and 2.04 (1.09, 3.82) in the highest tertile;
P-trendo0.0001.
Beaver Dam CKD Study baseline sample (N = 4880)
Hs-CRP and WBC
analyses (N = 4880)
Cohort random sample (N = 1789) for
TNF-alpha R2 and IL-6 analyses
Prevalent CVD (N = 262)
Missing covariates (N = 24)
Prevalent CVD (N = 720)
Missing covariates (N = 36)
Final analysis sample
N  = 4124
Final analysis sample
N = 1503
Figure 1 | Flowchart for sample construction of the cross-
sectional analysis. CKD, chronic kidney disease; CVD,
cardiovascular disease; Hs-CRP, high-sensitivity C-reactive protein;
IL, interleukin; TNF, tumor necrosis factor; WBC, white blood cell.
Beaver Dam CKD Study baseline sample (N = 4880)
Cohort random sample (N = 1789) for
TNF-alpha R2 and IL-6 analyses
Hs-CRP and WBC
analyses (N = 4880)
At least one follow-up exam data
available (N = 3770)
At least one follow-up exam data
available (N = 1363)
Prevalent CVD (N = 360)
Prevalent CKD (N = 514)
Missing covariates (N = 19)
Prevalent CVD (N =154)
Prevalent CKD (N =145)
Missing covariates (N =16)
Final analysis sample
N = 2877
Final analysis sample
N = 1048
Figure 2 | Flowchart for sample construction of the
longitudinal analysis. CKD, chronic kidney disease; CVD,
cardiovascular disease; Hs-CRP, high-sensitivity C-reactive protein;
IL, interleukin; TNF, tumor necrosis factor; WBC, white blood cell.
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DISCUSSION
In a population-based study of predominantly White subjects
from Wisconsin, we found that markers of inflammation,
including high-sensitivity CRP, TNF-aR2, WBC count, and
IL-6 levels, were positively associated with prevalent CKD at
baseline. However, in a longitudinal analysis examining the
risk of developing CKD over a 15-year follow-up period, only
TNF-aR2, WBC count, and IL-6 levels, not CRP levels, were
associated with incident CKD. The strongest and most
consistent association was observed for TNF-aR2. These
results remained relatively robust after multivariable adjust-
ment of confounders. Furthermore, the results also remained
consistent when we used a more specific definition to define
CKD.12 Results from our study further extend the current
understanding of the role of inflammatory markers in the
pathogenesis of CKD. Elevated CRP may be a marker of
heightened inflammatory processes known to be activated
secondary to kidney disease.13–15
Inflammation is a common feature of end-stage renal
disease.16–18 Several studies have also documented signifi-
cantly higher levels of markers of inflammation among
subjects with CKD,13,19 and have closely correlated inflam-
matory biomarker levels to changes in GFR20–22 among
subjects with CKD. In the current study, we found that all
markers of inflammation, including high-sensitivity CRP,
TNF-aR2, WBC count, and IL-6 levels, were related to
prevalent CKD in the cross-sectional analysis. However, CRP
was not associated with incident CKD in the longitudinal
analysis.
It is currently recognized that CKD is an independent risk
factor for cardiovascular disease and mortality.23,24 It has also
been shown that heightened inflammatory processes among
Table 1 | Baseline characteristics of cohort for the TNF-a receptor 2 analysis
Characteristica Total Tertile 1 Tertile 2 Tertile 3b P-valuec
Age, years 58.4 (0.3) 54.8 (0.5) 57.8 (0.5) 62.5 (0.5) o0.0001
Females, % 55.3 53.0 55.7 57.3 0.2536
Education, %
Below high school 19.6 13.2 16.0 29.5 o0.0001
High school 47.1 45.3 52.9 43.3 0.5956
Above high school 33.3 41.6 31.1 27.2 o0.0001
History of smoking, %
Never 44.0 43.3 43.7 45.0 0.6473
Former 34.8 38.4 34.9 31.2 0.0473
Current 21.2 18.3 21.4 23.8 0.0488
History of alcohol intake categories, %
Never 3.0 2.3 1.7 4.9 0.0480
Former 7.1 4.9 6.3 10.0 0.0086
Current drinker, o3 drinks per day 81.0 82.8 81.4 78.8 0.1771
Current drinker, X3 drinks per day 9.0 10.0 10.6 6.3 0.0862
Body mass index (BMI), kg/m2 28.7 (0.2) 27.5 (0.3) 29.1 (0.3) 29.7 (0.3) o0.0001
Diabetes mellitus, % 8.7 6.0 8.0 12.0 0.0052
Glycosylated hemoglobin, % 6.0 (1.5) 5.8 (0.1) 5.9 (0.1) 6.2 (0.1) 0.0025
Serum total cholesterol, mg/dl 231.4 (1.3) 233.6 (2.2) 231.9 (2.2) 228.7 (2.2) 0.2991
Hypertension, % 43.5 36.4 40.6 53.6 o0.0001
Systolic blood pressure, mmHg 129 (0.6) 126.8 (1.0) 128.2 (1.0) 133.4 (1.0) o0.0001
Diastolic blood pressure, mmHg 78.4 (0.3) 78.8 (0.5) 78.1 (0.5) 78.4 (0.5) 0.6726
Abbreviation: TNF-a, tumor necrosis factor alpha.
aNumbers in the table shown are mean (standard error) for continuous variable or percentage for categorical variables.
bTNF-a receptor 2 tertile cutoffs: Tertile 1 (men:p2043.9 pg/ml, women:p2078.5 pg/ml), Tertile 2 (men: 2044.0–2491.5 pg/ml, women: 2078.6–2544.5 pg/ml), Tertile 3 (men:
42491.5 pg/ml, women: 42544.5 pg/ml).
cP-value estimated by analysis of variance or w2-test as appropriate.
Table 2 |Mean levels of markers of inflammation by level of kidney function at the baseline examination
Mean (standard error) of the inflammatory marker measured in serum
Estimated glomerular filtration
rate (eGFR) category,
ml/min per 1.73m2
% Of study population
in each eGFR category
C-reactive protein
(mg/dl)
Tumor necrosis
factor-a receptor 2
(pg/ml)
White blood
cell count
(per 103
cells/mm3)
Interleukin-6
(pg/ml)
X60 84.9 3.9 (0.2) 2454.4 (27.8) 6.7 (0.03) 3.6 (0.3)
45–59 11.7 5.2 (0.4) 3273.2 (67.8) 7.3 (0.09) 4.1 (0.7)
30–44 2.9 7.8 (0.9) 4366.3 (153.8) 7.9 (0.2) 5.1 (1.9)
o30 0.5 12.4 (2.1) 10,449.5 (368.8) 9.1 (0.5) 8.4 (4.6)
P-trend o0.0001 o0.0001 0.002 0.04
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CKD subjects are partly responsible for this higher cardio-
vascular disease risk.14 Recent guidelines recommend the use
of CRP levels as a cardiovascular risk-stratification tool.25
Our results suggest that CRP measurement may identify
inflammatory processes occurring secondary to kidney
disease. CRP measurement may therefore be a risk-stratifica-
tion tool of cardiovascular risk due to kidney disease.
Several lines of recent evidence also suggest that
inflammatory processes may have a role in the development
of CKD. First, it is possible that inflammation could be
related to CKD development indirectly through its role in
comorbid conditions such as diabetes3 or hypertension.5
However, to examine this hypothesis, when we additionally
adjusted for diabetes and hypertension in the multivariable
model in Table 3, there was no change in hazard ratios,
suggesting that these conditions are probably not a mediator
in our study. Second, elevated circulating CRP levels
deposited in the glomerular endothelium may be the initial
injury that may then function through several interrelated
hypothesized mechanisms, including elevated angiotensin II
levels, increased transforming growth factor-b levels, de-
creased nephron mass, glomerular-capillary hypertension,
tubular cell hypertrophy, fibroblast proliferation, increased
type IV collagen synthesis, and interstitial inflammation,
leading to renal scarring.7,26 Third, several animal studies
also suggest that inflammation may contribute to CKD
development. Fattori et al.27 reported that transgenic mice
that constitutively express the inflammatory cytokine IL-6 in
the liver and secrete it into blood develop progressive kidney
disease. Bertani et al.8 reported that rabbits injected with
increasing doses of human recombinant TNF-a showed dose-
dependent glomerular endothelial cell damage. Rats pre-
treated with TNF-a and IL-6 showed increasing severity of
glomerular injury.9
In contrast to animal studies, there is limited evidence on
inflammatory processes and the risk of developing CKD from
human epidemiological studies.13,28,29 Previous cross-sec-
tional18,28,30 and case–control13 studies have reported an
association between inflammatory markers and CKD or
reduced kidney function. However, it is known that
inflammatory markers are secondarily elevated in subjects
with CKD13–15 and end-stage renal disease,16–18 reflecting a
heightened inflammatory response that occurs subsequent to
kidney disease. Therefore, a critical factor required to clarify
the direction of the putative inflammation–CKD association
is the need for a longitudinal study design among individuals
initially free of CKD at baseline. Even though one previous
longitudinal study demonstrated an association between CRP
levels and CKD, it included subjects with decreased kidney
function at baseline.31 It is possible that the observed
association between CRP and serum creatinine may be due
to CRP elevations occurring secondary to kidney disease.13–15
Table 3 | Cross-sectional association between markers of inflammation and the prevalence of chronic kidney disease (CKD)
Inflammatory
marker level
No.
at risk
CKD
cases
Unadjusted odds ratio
(95% confidence interval)
Age-sex-adjusted odds ratio
(95% confidence interval)
Multivariable-adjusted odds
ratio (95% confidence interval)a
Serum C-reactive protein (CRP)b
Tertile 1 1370 152 1 (Referent) 1 (Referent) 1 (Referent)
Tertile 2 1379 199 1.35 (1.08–1.69) 1.18 (0.97–1.45) 1.09 (0.89–1.35)
Tertile 3 1375 272 1.98 (1.59–2.45) 1.66 (1.38–2.01) 1.48 (1.22–1.79)
P-trend o0.0001 0.001 0.012
Serum tumor necrosis factor (TNF)-a receptor 2c
Tertile 1 501 29 1 (Referent) 1 (Referent) 1 (Referent)
Tertile 2 502 44 1.56 (0.96–2.54) 1.37 (0.87–2.18) 1.43 (0.89–2.27)
Tertile 3 500 146 6.71 (4.40–10.23) 3.39 (2.28–5.03) 3.50 (2.35–5.24)
P-trend o0.0001 o0.0001 o0.0001
Serum white blood cell (WBC) countd
Tertile 1 1378 129 1 (Referent) 1 (Referent) 1 (Referent)
Tertile 2 1375 231 1.95 (1.55–2.46) 1.48 (1.20–1.82) 1.32 (1.06–1.64)
Tertile 3 1371 263 2.30 (1.84–2.99) 1.99 (1.63–2.42) 1.94 (1.60–2.38)
P-trend o0.0001 o0.0001 o0.0001
Serum interleukin-6e
Tertile 1 501 48 1 (Referent) 1 (Referent) 1 (Referent)
Tertile 2 502 76 1.68 (1.15–2.47) 1.43 (1.01–2.03) 1.22 (0.86–1.76)
Tertile 3 500 95 2.21 (1.53–3.21) 1.86 (1.34–2.58) 1.77 (1.27–2.41)
P-trend o0.0001 o0.0001 0.002
aAdjusted for age (years), sex, education categories (ohigh school, high school,4high school), smoking (never, former, current), alcohol intake (never, former, current), body
mass index (kg/m2), diabetes (absent, present), glycosylated hemoglobin (%), hypertension (absent, present), mean arterial blood pressure (mmHg), and serum total
cholesterol (mg/dl).
bSerum CRP tertile cutoffs (mg/dl): Tertile 1 (men: o1.21mg/l, women: o1.29), Tertile 2 (men: 1.21–2.95, women: 1.29–3.34), and Tertile 3 (men: 42.95, women: 43.34).
cSerum TNF-a receptor 2 tertile cutoffs (pg/ml): Tertile 1 (men: o2084.8, women: o2136.6), Tertile 2 (men: 2084.8–2629.6, women: 2136.6–2715.1), and Tertile 3 (men:
42629.6, women: 42715.1).
dSerum white blood cell count tertile cutoffs (per 1000 cells/mm3): Tertile 1 (men: o6.4, women: o6.2), Tertile 2 (men: 6.4–7.9, women: 6.2–7.9), and Tertile 3 (men: 47.9,
women: 47.9).
eSerum interleukin-6 tertile cutoffs (pg/ml): Tertile 1 (men: o1.75, women:o1.82), Tertile 2 (men: 1.75–2.90, women: 1.82–3.04), and Tertile 3 (men:42.90, women:43.04).
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In this context, Erlinger et al.32 and Bash et al.33 analyzed
longitudinal data from the NHANES II follow-up study and
the Atherosclerosis Risk in Communities Study, respectively,
and showed that among subjects free of CKD at baseline,
elevated WBC count, a nonspecific marker of inflammation,
independently predicted the risk of developing CKD.
In the current study, we also found that elevated WBC
count was associated with incident CKD. However, we also
measured specific markers of inflammation, including high-
sensitivity CRP, TNF-aR2, and IL-6 levels, and examined
their association with the risk of developing incident CKD
over a 15-year follow-up period in the longitudinal analysis.
We found that only TNF-aR2 and IL-6 levels, not CRP levels,
predicted the risk of developing incident CKD. In contrast,
CRP, TNF-aR2, and IL-6 levels were all associated with
prevalent CKD in the cross-sectional analysis. Finally, the fact
that we obtained consistent results when we repeated the
main analysis defining CKD using a more specific definition
recently suggested by Bash et al.12 suggests that these results
are not likely to be due to chance.
Our results suggest that, similar to animal studies,8,9
inflammatory mechanisms may be involved in the etiology of
CKD in humans also and that TNF-aR2 level elevations are
an early marker of these mechanisms. The observed lack of
association between CRP levels and incident CKD may be
due to several possible reasons. Elevation of CRP levels may
be a marker/intermediary effect of antecedent inflammatory
processes (e.g., TNF-a-mediated inflammation). As a result,
CRP elevations may be evident only in relatively later stages
of kidney disease development, and therefore not useful for
early prediction of CKD. Alternatively, it is also possible that
any CRP–CKD association may entirely be explained by
confounders that were adjusted in our multivariable model,
such as age, gender, body mass index, diabetes, or hyperten-
sion. Finally, if the true CRP association is relatively weak,
statistical power could be lower than for TNF-aR2.
Strengths of this study include its population-based
sample, high participation rate, use of standardized protocols
for exposure and outcome measurement, and the availability
of specific markers of inflammation, including CRP and
TNF-aR2 levels. We had validated measures of kidney
function, including eGFR, using standardized serum creati-
nine as per the recent National Kidney Disease Education
Program guidelines.34 A main study limitation is the lack of
information on a marker of kidney injury such as 24-h urine
protein or urinary albumin/creatinine ratio. Second, similar
to previously published studies using stored baseline blood,35
we measured serum TNF-aR2 levels in the current study as a
measure of TNF-a-related inflammation. Third, as our study
sample is composed of predominantly White participants,
Table 4 | Longitudinal association between markers of inflammation and 15-year incidence of chronic kidney disease (CKD)
Inflammatory
marker level
No.
at risk
CKD
cases
Unadjusted
hazard ratio
(95% confidence interval)
Age-sex-adjusted
hazard ratio
(95% confidence interval)
Multivariable-adjusted
hazard ratio 1
(95% confidence interval)a
Multivariable-
adjusted hazard ratio 2
(95% confidence interval)a
Serum C-reactive protein (CRP)b
Tertile 1 960 197 1 (Referent) 1 (Referent) 1 (Referent) 1 (Referent)
Tertile 2 961 234 1.19 (1.00–1.40) 1.13 (0.95–1.33) 1.10 (0.92–1.32) 1.06 (0.89–1.27)
Tertile 3 956 244 1.24 (1.05–1.47) 1.19 (0.97–1.46) 1.14 (0.95–1.37) 1.09 (0.91–1.29)
P-trend 0.001 0.09 0.21 0.42
Serum tumor necrosis factor (TNF)-a receptor 2c
Tertile 1 349 54 1 (Referent) 1 (Referent) 1 (Referent) 1 (Referent)
Tertile 2 350 82 1.51 (1.11–2.06) 1.49 (1.06–2.09) 1.47 (1.01–2.14) 1.40 (0.94–2.09)
Tertile 3 349 132 2.44 (1.85–3.23) 2.68 (1.73–4.15) 2.49 (1.66–3.74) 2.10 (1.55–2.84)
P-trend o0.0001 o0.0001 o0.0001 o0.0001
Serum white blood cell (WBC) countd
Tertile 1 961 140 1 (Referent) 1 (Referent) 1 (Referent) 1 (Referent)
Tertile 2 960 252 1.80 (1.50–2.17) 1.63 (1.36–1.95) 1.58 (1.29–1.94) 1.41 (1.16–1.70)
Tertile 3 956 293 2.10 (1.76–2.52) 2.04 (1.70–2.45) 1.98 (1.68–2.33) 1.90 (1.59–2.27)
P-trend o0.0001 o0.0001 0.0011 0.0014
Serum interleukin-6e
Tertile 1 351 51 1 (Referent) 1 (Referent) 1 (Referent) 1 (Referent)
Tertile 2 348 97 1.92 (1.41–2.60) 1.43 (0.98–2.07) 1.39 (0.95–2.03) 1.32 (0.89–1.97)
Tertile 3 349 120 2.37 (1.77–3.17) 1.72 (1.11–2.67) 1.57 (1.04–2.37) 1.45 (0.99–2.14)
P-trend o0.0001 0.022 0.043 0.073
aMultivariable-adjusted hazard ratio 1: adjusted for age (years), sex, education categories (ohigh school, high school,4high school), smoking (never, former, current), alcohol
intake (never, former, current), body mass index (kg/m2), glycosylated hemoglobin (%), mean arterial blood pressure (mmHg), and serum total cholesterol (mg/dl);
Multivariable-adjusted hazard ratio 2: additionally adjusted for diabetes (absent, present) and hypertension (absent, present).
bSerum C-reactive protein cutoffs (mg/dl): Tertile 1 (men: o1.13, women: o1.19), Tertile 2 (men: 1.13–2.60, women: 1.19–2.99), and Tertile 3 (men: 42.60, women: 42.99).
cSerum TNF-a receptor 2 tertile cutoffs (pg/ml): Tertile 1 (men: o2043.9, women: o2078.5), Tertile 2 (men: 2043.9–2491.5, women: 2078.5–2544.5), and Tertile 3 (men:
42491.5, women: 42544.5).
dSerum white blood cell count tertile cutoffs (per 1000 cells/mm3): Tertile 1 (men: o6.2, women: o5.8), Tertile 2 (men: 6.2–7.8, women: 5.8–7.3), and Tertile 3 (men: 47.8,
women: 47.3).
eSerum interleukin-6 tertile cutoffs (pg/ml): Tertile 1 (men: o1.5, women: o1.6mg/l), Tertile 2 (men: 1.5–2.6, women: 1.6–2.7), and Tertile 3 (men:42.6, women: 42.7).
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our results may not be generalizable to other racial–ethnic
groups. Fourth, the markers of inflammation that we studied
may be affected by intervening episodes of acute renal failure/
acute kidney injury for which we did not have data available.
As acute renal failure/acute kidney injury is also a risk factor
for incident CKD, it is possible that the observed association
in our study is be explained by this unmeasured confounder.
In conclusion, results from this study support the
hypothesis of an association between elevated markers of
inflammation—including TNF-aR2, WBC count, and IL-6
levels—and the risk of developing CKD, suggesting a role for
inflammatory mechanisms in the etiology of CKD. A
practical application of our findings is that, if replicated in
other studies, these markers may be a potential future way of
assessing subjects who are more likely to develop CKD.
MATERIALS AND METHODS
The Beaver Dam Chronic Kidney Disease Study is a prospective
cohort study of risk factors for CKD. The study was designed as an
ancillary study within the population-based Beaver Dam cohort.
The exposure, outcome, and covariate information for Beaver Dam
Chronic Kidney Disease Study were obtained by combining (1) the
newly measured biomarker data, including serum creatinine and
markers of inflammation, measured from stored blood in two
related prospective cohort studies that followed the same set of study
subjects of the Beaver Dam cohort, the Beaver Dam Eye study,36,37
and the Epidemiology of Hearing Loss Study,38,39 and (2)
questionnaire, physical examination, and laboratory measurement
data already collected in these studies. The methods used to identify
and describe the Beaver Dam population have appeared in previous
reports.36–39
In brief, a private census of the population of Beaver Dam,
Wisconsin, was carried out from September 1987 to May 1988 to
identify all residents in the city or township of Beaver Dam who
were in the age group of 43–84 years. Of the 5924 eligible individuals
(98% Caucasians), 4926 (83.1%) participated in the baseline
examination of Beaver Dam Eye study between 1 March 1988 and
14 September 1990. Comparisons between participants and non-
participants at the time of the baseline examination have appeared
elsewhere.37 The Beaver Dam Eye study participants alive as on 1
March 1993, were eligible for the baseline examination for
Epidemiology of Hearing Loss Study (n¼ 4541), which occurred
at the time of the 5-year follow-up visit for the eye study.
Therefore, the assembled Beaver Dam Chronic Kidney Disease
Study data involved a baseline examination from 1988 to 1990, a
5-year follow-up examination from 1993 to 1995, a 10-year
follow-up examination from 1998–2000, and a 15-year follow-up
examination from 2003–2005. Approximately 73% of the surviving
Beaver Dam participants were studied at the follow-up examina-
tions. Written informed consent was obtained from each subject at
each examination. The study was approved by the Human Subjects
Committee of the University of Wisconsin School of Medicine and
Public Health, Madison, WI.
The current paper presents two sets of analyses: (1) a cross-
sectional analysis with prevalent CKD as the outcome of interest and
(2) a longitudinal analysis with 15-year incident CKD as the
outcome of interest. The sample sizes were different for each
inflammatory biomarker, as high-sensitivity CRP and WBC count
were available on all baseline cohort subjects (n¼ 4880), whereas
TNF-aR2 and IL-6 were measured only in a random sample of the
baseline cohort (n¼ 1789). The sample construction for the cross-
sectional and longitudinal analysis are presented in Figures 1 and 2,
respectively.
Exposure ascertainment
The baseline and follow-up examinations included measurement of
weight, height, systolic, and diastolic blood pressure by trained
observers, and administering a standardized questionnaire that
collected information regarding participants’ demographic charac-
teristics, details regarding cigarette smoking, alcohol intake, medical
histories, and medications taken, including physician-diagnosed
diabetes, hypertension, or cardiovascular disease. Non-fasting blood
specimens were obtained for measurement of plasma glucose,
glycosylated hemoglobin, serum total cholesterol, and high-density
lipoprotein cholesterol.
Age was defined as the participants’ age at the time of the
baseline examination. Education was categorized as less than high
school, high school, or beyond high school. Body mass index was
defined as participants’ weight in kilograms divided by their height
in meters squared. Hypertension was defined as a systolic blood
pressure of 140mmHg or higher, and/or a diastolic blood pressure
90mmHg or higher, and/or the combination of self-reported
hypertension diagnosis by a physician, and use of antihypertensive
medications. Persons were defined as having diabetes mellitus if they
had a history of diabetes diagnosis by a physician and were treated
with insulin, oral hypoglycemic agents or diet, or were newly
classified as having diabetes based on the presence of a casual blood
sugar valueX200mg/dl (11.1mmol/l) or a glycosylated hemoglobin
value that was 42 standard deviations above the mean for a given
age/gender group (for those in the age group of 43–54 years, men
49.5% and women 49.6%; for those in the age group of 55–64
years, men49.4% and women410.0%; for those in the age group
of 65–74 years, men49.6% and women49.6%; and for thoseX75
years, men 49.5% and women 49.6%).
At the baseline and follow-up examinations, additional blood
samples were stored in freezers at 80 1C, until the time of
laboratory analysis. Quality control samples were routinely frozen
with study participant samples. Baseline frozen samples were
analyzed for high-sensitivity CRP, TNF-aR2, and IL-6 levels.
High-sensitivity CRP was measured in serum in all eligible baseline
study subjects (n¼ 4880) using latex-particle-enhanced immuno-
turbidimetric assay kit (Kamiya Biomedical Company, Seattle,
WA) and read on the Roche/Hitachi 911 (Roche Diagnostics,
Indianapolis, IN). The reference range is 0–0.5mg/dl. The inter-assay
coefficient of variability range was 4.5%. TNF-aR2 levels were
measured in serum in a random sample of baseline cohort
participants (n¼ 1789) using the quantitative sandwich enzyme
technique of the enzyme-linked immunosorbent assay QuantiKine
kit from R&D Systems (Minneapolis, MN). The intensity of
the color is measured on a SpectraMax spectrophotometer
(Molecular Devices, Sunnyvale, CA). The inter-assay coefficient of
variability was 3.5–5.1%. IL-6 level was measured in serum using
the quantitative sandwich enzyme technique of the enzyme-linked
immunosorbent assay QuantiKine High Sensitivity kit from R&D
Systems. The intensity of the color is measured on a Spectra-
Max spectrophotometer (Molecular Devices). The inter-assay coeffi-
cient of variability range reported was 6.5–9.6%. WBC count
was determined using a Coulter counter method. Reliability
coefficients, based on blind replicate control data, ranged from
0.96 to 1.00.
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Serum was stored without preservative at 80 1C in cryogenic vials
with O-rings for up to 17 years, until the vials were shipped on dry
ice to the University of Minnesota laboratory for carrying out the
analyses reported in this study. Creatinine level was measured in
serum from all study examinations by reflectance spectrophotome-
try on the Vitros analyzer (Johnson & Johnson Clinical Diagnostics,
Rochester, NY), consistent with the current National Kidney Disease
Education Program recommendations for standardizing serum
creatinine measurement.34 The laboratory coefficient of variability
was 2.2%.
Glomerular filtration rate was estimated from serum creatinine
using the re-expressed Modification of Diet in Renal Disease
equation is defined as follows: eGFR¼ 175 (serum creatinine in
mg/dl)1.154 age0.203 (0.742 for women). CKD was defined as
an eGFR of o60ml/min per 1.73m2, based on the US National
Kidney Foundation Kidney Disease Outcome Quality Initiative
working group definition,40 and the Kidney Disease Improving
Global Outcomes definition.41 Prevalent CKD was defined as the
presence of CKD at the baseline examination. Death due to CKD
(n¼ 6) was defined as the underlying cause of death reported as
chronic renal disease (ICD-9 codes 581–583 or 585–588); hyperten-
sive renal disease (ICD-9 code 403); hypertensive heart and renal
disease (ICD-9 code 404); unspecified disorder of kidney and ureter
(ICD-9 code 593.9); diabetes with renal manifestations (ICD-9 code
250.3); kidney transplant, renal dialysis, or adjustment/fitting of
catheter (ICD-9 codes V42.0, V45.1 or V56); and hemodialysis
(ICD-9 code 39.95) or peritoneal dialysis (ICD-9 code 54.98),
without acute renal failure (ICD-9 codes 584, 586, 788.9, and 958.5).
Incident CKD was defined as the new development of CKD at the
5-, 10- or 15-year follow-up examination or subjects who died
because of CKD among subjects free of CKD at baseline.
Statistical methods
We were interested in the association between markers of
inflammation (serum CRP, TNF-aR2, WBC count, and IL-6 levels)
and CKD. We performed two sets of analyses; the first set examined
the cross-sectional association between these inflammatory markers
and prevalent CKD, and the second set examined the longitudinal
association with 15-year incident CKD. We categorized inflamma-
tory markers into tertiles for the analysis. We used the w2-test to
compare categorical variables, and analysis of variance to compare
continuous variables between increasing categories of TNF-aR2. We
used multivariable proportional hazards models with discrete
handling of ties to determine the Hazards ratio and 95 percent
confidence interval (CI) of 15-year incident CKD, controlling
simultaneously for potential confounders. Age and sex are well-
known confounders for the inflammation–CKD association. There-
fore, we choose to present our results starting from the age- and
sex-adjusted model rather than the unadjusted model. Subsequently,
we are presenting two nested proportional hazards models in this
paper: an age- (years) and sex-adjusted model, and a multivariable-
adjusted model, including additional adjustment for education
(ohigh school, high school,4high school), smoking (never, former,
current), alcohol intake (never, former, current), body mass index
(kg/m2), diabetes mellitus (absent, present), glycosylated hemo-
globin level (%), hypertension (absent, present), mean arterial blood
pressure (mmHg), and serum total cholesterol (mg/dl). Linear
trends across tertiles were assessed by including tertile-specific
median inflammatory biomarker values as a continuous variable in
the proportional hazards regression models.
We also performed the following supplementary analyses. First, to
examine whether the positive association observed between increas-
ing TNF-aR2 levels and 15-year incident CKD in the longitudinal
analysis was independent of other inflammatory markers (CRP, WBC
count, and IL-6 levels), we additionally adjusted for levels of these
markers as a continuous variable in the multivariable model. Second,
to rule out the possibility of reverse causality, we repeated the main
analysis after excluding the CKD cases occurring during the initial
5 years of follow-up. Finally, we repeated the main analyses using a
more specific definition of CKD by Bash et al.,12 defined as both an
eGFR falling below 60ml/min per 1.73m2 (our main definition) and
a decrease in eGFR of at least 25% over the follow-up period.
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